Human Genome Sciences, Inc. (Nasdaq: HGSI) will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA® (belimumab), the first approved drug ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the J.P. Morgan 30th Annual Healthcare Conference will be webcast and may be accessed at www.hgsi.com. ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2011 Deutsche Bank BioFEST Conference will be webcast and may be accessed at www.hgsi.com. ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Piper Jaffray 23rd Annual Health Care Conference will be webcast and may be accessed at ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2011 Annual Credit Suisse Health Care Conference will be webcast and may be accessed at ... read more

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the completion of its offering and sale of $494.5 million in aggregate principal amount of 3.00% Convertible Senior Notes due ... read more

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that several abstracts related to BENLYSTA® (belimumab) and systemic lupus erythematosus (SLE) will be presented at the annual meeting of ... read more

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the exercise in full of the underwriter’s option to purchase an additional $64.5 million principal amount of its Convertible Senior ... read more

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has priced an underwritten public offering of $430 million aggregate principal amount of Convertible Senior Notes due 2018, ... read more

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter ended September 30, 2011, and provided highlights of recent key developments. ... read more

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2011. These ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the UBS Global Life Sciences Conference will be webcast and may be accessed at www.hgsi.com. ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Bank of America Merrill Lynch Healthcare Conference will be webcast and may be accessed at ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Morgan Stanley Global Healthcare Conference will be webcast and may be accessed at www.hgsi.com. ... read more

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at Baird's 2011 Health Care Conference will be webcast and may be accessed at www.hgsi.com. ... read more

ROCKVILLE, MD -- (Marketwire) -- 03/09/09 -- -- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C -- ... read more

ROCKVILLE, MD -- (Marketwire) -- 02/02/09 -- Human Genome Sciences, Inc. (NASDAQ: HGSI) today announced that it has begun delivery of 20,000 doses of its human monoclonal antibody drug ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the treatment of inhalation anthrax. ABthrax is a first-in-class treatment for anthrax, and the ... read more